Becton, Dickinson and Company (NYSE: BDX) is a global medical technology firm headquartered in Franklin Lakes, New Jersey. BDX specializes in the development, manufacturing, and sale of medical devices, laboratory equipment, and diagnostic products.
Key Takeaways:
- BDX stock is projected to show steady growth from 2024 to 2050
- The company’s focus on innovation and global expansion supports positive forecasts
- Potential for significant returns for long-term investors
- Compound Annual Growth Rate (CAGR) indicates robust performance
- Market trends and economic factors will influence stock performance
Overview of Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that operates in the healthcare industry. Founded in 1897, BD has a rich history of innovation and has grown to become a leader in medical supplies, devices, laboratory equipment, and diagnostic products.
History of the Company
- 1897: Founded in New York City by Maxwell Becton and Fairleigh S. Dickinson.
- 1906: Opened the first syringe and needle factory in the United States. Incorporated as Becton, Dickinson & Company.
- 1925: Fairleigh Dickinson patented the Luer-Lok tip, becoming the standard for syringes in the US.
- 1949: Entered the diagnostic medicine market with the Evacutainer blood collection device.
- 1954: Introduced the first completely disposable glass syringe: Hypak.
- 1962: Introduced the disposable Plastipak syringe.
- 2000s-present: Continued growth through major acquisitions like CareFusion (2014) and C.R. Bard (2017).
Becton, Dickinson and Company Profile
| Country | United States |
| Ticker Symbol | BDX |
| Exchange | NYSE |
| Founded | 1897 |
| IPO Date | 1962 |
| Industry | Medical Technology |
| Sector | Healthcare |
| Employees | 73,000 |
| CEO | Thomas E. Polen |
| Market Cap (August 9, 2024) | $68.19 billion |
| Website | bd |
Becton, Dickinson and Company (BDX) Balance Sheet Analysis
Becton, Dickinson and Company’s (NYSE: BDX) 2023 balance sheet reveals a stable financial position. Total assets slightly decreased to $52.78 billion, while total liabilities reduced to $26.98 billion, indicating improved debt management.
The company’s total equity increased to $25.80 billion, reflecting enhanced shareholder value. Total capitalization rose to $40.54 billion, and working capital significantly improved to $2.04 billion, suggesting better short-term liquidity.
Despite negative net tangible assets of $9.67 billion, this figure improved from the previous year. Total debt decreased to $15.88 billion, while net debt reduced to $14.46 billion, showing progress in debt reduction.
Overall, BDX’s 2023 balance sheet demonstrates financial stability with notable improvements in equity, working capital, and debt management, despite a minor decrease in total assets.
Balance Sheet Data Source: finance.yahoo
Becton, Dickinson and Company Stock Price History
Becton, Dickinson and Company (NYSE: BDX) had its IPO in the year 1962. Becton Dickinson (BDX) had five stock splits: 2:1 in 1986, 1993, and 1996; 2:1 in 1998; and 1.025:1 in 2022. One pre-1986 share equals 16.4 shares today.1
As of August 9, 2024, the price of BDX stock stands at $235.90.
BDX Stock Price Forecast 2024
For the remainder of 2024, we anticipate robust growth for BDX stock. The company’s strong fundamentals and ongoing research and development efforts are likely to support this upward trend. Projected growth of 10% is expected, driven by BD’s innovative product pipeline and expanding global market presence. The healthcare sector’s increasing focus on advanced medical technologies aligns well with BD’s core competencies, potentially boosting investor confidence and stock performance.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2024 | $205.90 | $259.49 | $311.39 |
BDX Stock Price Forecast 2025
In 2025, we expect BDX to continue its upward momentum with a projected growth of 11%. The company’s focus on expanding its product portfolio and penetrating emerging markets could drive this growth. BD’s strategic investments in digital health solutions and AI-driven diagnostics are likely to bear fruit, potentially opening new revenue streams. The increasing global healthcare expenditure, particularly in developing economies, presents significant opportunities for BD’s expansion.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2025 | $261.85 | $288.03 | $345.64 |
BDX Stock Price Forecast 2026
For 2026, our analysis suggests a growth rate of 12%. This increase could be attributed to the maturation of recent investments and the potential launch of new products. BD’s commitment to sustainability and environmental stewardship may enhance its brand value and attract socially conscious investors. The company’s efforts in developing eco-friendly medical devices could set it apart in an increasingly environmentally aware market, potentially boosting stock performance.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2026 | $293.27 | $322.60 | $387.12 |
BDX Stock Price Forecast 2027
In 2027, we anticipate continued steady growth for BDX stock, with a projected increase of 13%. The company’s strong market position and ongoing innovation efforts are expected to support this trend. BD’s focus on personalized medicine and genomics could lead to breakthrough products, potentially revolutionizing patient care. The increasing prevalence of chronic diseases worldwide may drive demand for BD’s diagnostic and treatment solutions, further supporting stock price growth.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2027 | $331.40 | $364.54 | $437.45 |
BDX Stock Price Forecast 2028
For 2028, our forecast indicates an acceleration in growth to 14%. This could be driven by expanding global healthcare needs and BD’s ability to meet these demands. The company’s investments in automation and robotics in healthcare settings may start yielding significant returns. BD’s potential advancements in minimally invasive surgical technologies could capture a larger market share, positively impacting stock performance.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2028 | $377.80 | $415.58 | $498.70 |
BDX Stock Price Forecast 2029
In 2029, we expect BDX to maintain its growth momentum with a projected increase of 15%. The company’s strategic initiatives and market adaptability are likely to play crucial roles in this continued upward trend. BD’s potential breakthroughs in drug delivery systems and wearable medical devices could open up new market opportunities. The increasing focus on home healthcare solutions, accelerated by global events, may provide BD with additional growth avenues.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2029 | $434.47 | $477.92 | $573.50 |
BDX Stock Price Forecast 2030
As we enter the new decade, our 2030 forecast for BDX stock remains optimistic, with a projected growth of 14%. The company’s long-term vision and commitment to innovation could drive substantial growth. BD’s potential advancements in bioprocessing technologies may position it as a key player in the rapidly growing biopharmaceutical industry. The company’s efforts in developing next-generation sequencing technologies could also contribute to its market leadership and stock performance.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2030 | $495.30 | $544.83 | $653.80 |
Related: GSK plc (GSK) Stock Forecast & Price Prediction
BDX Stock Price Forecast 2031
In 2031, we anticipate BDX to continue its upward trajectory with a projected growth of 13%. The company’s established market presence and ongoing expansion efforts are expected to contribute to this growth. BD’s potential innovations in point-of-care testing and mobile health solutions could revolutionize disease diagnosis and management. The increasing global focus on pandemic preparedness may drive demand for BD’s infectious disease diagnostics and vaccine delivery systems.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2031 | $559.69 | $615.66 | $738.79 |
BDX Stock Price Forecast 2032
For 2032, our analysis suggests a growth rate of 12%. This could be attributed to the potential fruition of long-term research and development projects. BD’s investments in artificial intelligence and machine learning for healthcare applications may start yielding significant returns. The company’s efforts in developing sustainable healthcare solutions could resonate with an increasingly environmentally conscious market, potentially boosting investor interest and stock performance.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2032 | $626.85 | $689.54 | $827.45 |
BDX Stock Price Forecast 2033
In 2033, we expect BDX to maintain its strong growth momentum with a projected increase of 11%. The company’s adaptability to evolving healthcare needs could be a key driver of this continued success. BD’s potential advancements in regenerative medicine and tissue engineering may open up new market opportunities. The company’s focus on developing integrated healthcare solutions that combine devices, software, and analytics could set it apart in an increasingly digital healthcare landscape.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2033 | $695.80 | $765.39 | $918.47 |
BDX Stock Price Forecast 2034
Our 2034 forecast for BDX stock remains bullish, with a projected growth of 10%. The company’s strategic positioning in high-growth markets could contribute to this projected increase. BD’s potential breakthroughs in nanotechnology-based medical devices may revolutionize targeted drug delivery and diagnostics. The company’s efforts in developing solutions for emerging global health challenges could further strengthen its market position and support stock price growth.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2034 | $765.38 | $841.93 | $1,010.32 |
BDX Stock Price Forecast 2035
For 2035, we anticipate BDX to continue its impressive growth with a projected increase of 11%. The company’s focus on technological advancements and market expansion could drive this upward trend. BD’s potential innovations in personalized medicine and genomics-based therapies may open up new revenue streams. The increasing global focus on healthcare accessibility could provide BD with opportunities to expand its reach in underserved markets.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2035 | $849.57 | $934.54 | $1,121.45 |
BDX Stock Price Forecast 2036
In 2036, our analysis suggests another year of strong growth for BDX stock, with a projected increase of 12%. The company’s ability to capitalize on emerging healthcare trends could be a key factor in this projection. BD’s potential advancements in 3D bioprinting technologies may revolutionize organ transplantation and tissue engineering. The company’s efforts in developing closed-loop systems for chronic disease management could significantly improve patient outcomes and drive market demand.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2036 | $951.52 | $1,046.68 | $1,256.02 |
BDX Stock Price Forecast 2037
For 2037, we expect BDX to maintain its upward momentum with a projected growth of 13%. The company’s strong market position and continued innovation efforts are likely to support this growth. BD’s potential breakthroughs in gene therapy delivery systems could position it as a key player in the rapidly evolving field of genetic medicine. The company’s focus on developing AI-powered diagnostic tools may significantly enhance disease detection and treatment planning.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2037 | $1,075.22 | $1,182.75 | $1,419.30 |
BDX Stock Price Forecast 2038
In 2038, our forecast indicates continued robust growth for BDX stock, with a projected increase of 14%. The company’s global presence and diversified product portfolio could be key drivers of this projected increase. BD’s potential innovations in robotic surgery and augmented reality-guided procedures may revolutionize surgical practices. The company’s efforts in developing advanced biosensors and continuous monitoring devices could open up new markets in preventive healthcare.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2038 | $1,225.75 | $1,348.34 | $1,618.01 |
BDX Stock Price Forecast 2039
For 2039, we anticipate another year of strong performance for BDX stock, with a projected growth of 15%. The company’s ability to adapt to changing market conditions and healthcare needs could contribute to this growth. BD’s potential advancements in organ-on-a-chip technology may revolutionize drug discovery and personalized medicine. The company’s focus on developing sustainable and eco-friendly medical devices could resonate with increasingly environmentally conscious consumers and investors.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2039 | $1,409.61 | $1,550.59 | $1,860.71 |
BDX Stock Price Forecast 2040
As we approach 2040, our analysis suggests continued impressive growth for BDX stock, with a projected increase of 14%. The company’s long-term strategies and market leadership position are expected to drive this upward trend. BD’s potential breakthroughs in quantum computing applications for healthcare could revolutionize drug discovery and personalized treatment plans. The company’s efforts in developing next-generation vaccine technologies may position it as a key player in global health security.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2040 | $1,606.96 | $1,767.67 | $2,121.20 |
BDX Stock Price Forecast 2050
Looking ahead to 2050, our long-term forecast for BDX stock remains highly optimistic. While predicting so far into the future involves considerable uncertainty, we believe BDX’s commitment to innovation and its crucial role in the healthcare industry position it for substantial growth. The projected growth over this extended period reflects the potential for BD to continue its trajectory of innovation and market leadership. By 2050, BD could be at the forefront of groundbreaking medical technologies that we can scarcely imagine today, potentially revolutionizing healthcare delivery and patient outcomes.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2050 | $6,500 | $6,700 | $6,900 |
Conclusion
Our comprehensive analysis of Becton, Dickinson and Company (NYSE: BDX) stock price forecasts from 2024 to 2050 paints a picture of steady and impressive growth. We project the stock to reach an average price of $6,700 by 2050, representing a remarkable increase over this extended period.
This projected growth is underpinned by several factors:
- BD’s strong market position in the healthcare industry
- The company’s commitment to innovation and research
- Expansion into emerging markets
- Diversification of product portfolio
- Adaptation to evolving healthcare needs and technologies
FAQs
1. What is the future of BDX share price?
Our forecast suggests a positive future for BDX share price. The stock is projected to show steady growth from 2024 to 2050, with annual growth rates ranging between 10% and 15%. By 2050, the average price is forecasted to reach $6,700.
2. What is the BDX share prediction for 2030?
According to our forecast, the BDX share price prediction for 2030 is:
- Low Price: $495.30
- Average Price: $544.83
- High Price: $653.80
This represents a projected growth of 14% from the previous year.
3. What is the BDX 10 year outlook?
The 10-year outlook for BDX (from 2024 to 2034) appears strong. Our projections show consistent growth over this period. By 2034, we forecast:
- Low Price: $765.38
- Average Price: $841.93
- High Price: $1,010.32
This represents significant growth from the 2024 starting price of $235.90.
4. Is BDX a buy, hold, or sell?
BDX could be considered a potential “buy” or “hold” for long-term investors. The forecast shows steady annual growth rates between 10% and 15% from 2024 to 2050, indicating strong long-term potential. The company’s commitment to research and development in areas like AI, robotics, and personalized medicine suggests potential for future market leadership.
5. Who are the major competitors of BDX?
Becton, Dickinson and Company (BD) operates in the medical technology and life sciences sectors, where it has several major competitors. These competitors typically offer similar products and services in areas like medical devices, diagnostic systems, and biosciences. Here are some of the major competitors of BD:
- Medtronic plc (NYSE: MDT): A global leader in medical technology, Medtronic offers a wide range of products and therapies in cardiovascular, medical surgical, and diabetes care, among other areas.
- Thermo Fisher Scientific Inc. (NYSE: TMO): A significant player in the life sciences sector, Thermo Fisher provides a variety of laboratory equipment, chemicals, and services that compete with BD’s biosciences and diagnostics offerings.
- Abbott Laboratories (NYSE: ABT): Abbott competes with BD in diagnostics, medical devices, and pharmaceutical products, particularly in areas like diabetes care and diagnostics.
- Johnson & Johnson (NYSE: JNJ): Through its subsidiaries, Johnson & Johnson offers a wide range of products, including medical devices and diagnostics that overlap with BD’s product lines.
- Stryker Corporation (NYSE: SYK): Stryker is another significant competitor in the medical devices space, especially in surgical equipment and technologies, which overlap with some of BD’s product lines.
- Cardinal Health, Inc. (NYSE: CAH): While primarily a healthcare services and distribution company, Cardinal Health also competes with BD through its medical products and laboratory services.
- Siemens Healthineers AG (ETR: SHL): Siemens Healthineers competes with BD in the diagnostics and imaging market, offering advanced laboratory diagnostics and point-of-care solutions.
These companies are among the leading competitors that challenge BD across various segments of the healthcare and life sciences industries.
Disclaimer:
The stock price predictions provided herein are based on historical data, current market trends, and analysis. However, past performance does not guarantee future results. Stock markets are inherently volatile and subject to numerous economic, political, and market factors that can cause rapid and unpredictable fluctuations in stock prices. The information provided is for educational and informational purposes only and should not be construed as financial advice. It is strongly recommended that you consult with a qualified financial advisor before making any investment decisions. Invest responsibly and consider your individual financial situation, risk tolerance, and investment objectives before acting on any information provided.
Source:
